Burns Matteson Capital Management LLC Has $424,000 Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Burns Matteson Capital Management LLC cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMNFree Report) by 5.5% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,170 shares of the life sciences company’s stock after selling 185 shares during the quarter. Burns Matteson Capital Management LLC’s holdings in Illumina were worth $424,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Empowered Funds LLC boosted its holdings in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after purchasing an additional 66 shares during the period. Caprock Group LLC lifted its position in Illumina by 3.0% in the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after buying an additional 83 shares in the last quarter. Integrated Advisors Network LLC boosted its stake in shares of Illumina by 2.0% during the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after buying an additional 90 shares during the period. Stephens Inc. AR grew its holdings in shares of Illumina by 1.4% during the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares in the last quarter. Finally, Moors & Cabot Inc. increased its stake in shares of Illumina by 1.7% in the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after acquiring an additional 95 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. Leerink Partners lifted their price objective on Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Royal Bank of Canada reduced their price target on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday. UBS Group increased their price objective on Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Canaccord Genuity Group reduced their target price on shares of Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research note on Friday. Finally, Stephens boosted their target price on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Nine analysts have rated the stock with a hold rating, eleven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $161.40.

Check Out Our Latest Analysis on Illumina

Illumina Price Performance

NASDAQ:ILMN opened at $111.06 on Monday. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a one year low of $100.08 and a one year high of $156.66. The company has a fifty day moving average price of $136.70 and a 200 day moving average price of $135.43. The stock has a market cap of $17.61 billion, a P/E ratio of -14.46 and a beta of 1.10.

Illumina (NASDAQ:ILMNGet Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. Analysts anticipate that Illumina, Inc. will post 4.42 earnings per share for the current year.

Illumina Profile

(Free Report)

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.

Featured Stories

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMNFree Report).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.